Reach Us +44-1522-440391
Dual Blocking of the Renin Angiotensin System: A Settled Issue? | OMICS International | Abstract
ISSN: 2167-1095

Journal of Hypertension: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article

Dual Blocking of the Renin Angiotensin System: A Settled Issue?

Luis I Juncos* and Caputo Joaquin

J Robert Cade Foundation, Argentina

*Corresponding Author:
Luis I Juncos
J Robert Cade Foundation
Cordoba, Argentina
Tel: 543516533490
E-mail: [email protected]

Received Date: February 28, 2014; Accepted Date: April 08, 2014; Published Date: April 10, 2014

Citation: Juncos LI, Joaquin C (2014) Dual Blocking of the Renin Angiotensin System: A Settled Issue? J Hypertens 3:148. doi:10.4172/2167-1095.1000148

Copyright: © 2014 Juncos LI, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


The renin-angiotensin system (RAS) exerts wide-ranging effects on cardiovascular and kidney function. Oddly, this system that was designed to preserve normal hemodynamics may become harmful in certain clinical situations. For this reason, RAS inhibition is a highly effective therapeutic approach, not only to lower blood pressure but also to reduce kidney and cardiovascular disease morbidity and mortality. In some patients however, these beneficial effects of RAS inhibition are incomplete or absent. For these less than ideal results, several reasons have been proposed; e.g.: angiotensin escape, over production of angiotensin from negative feedback, local tissue RAS, etc. To secure better RAS blocking, some clinicians have proposed increasing the dose of angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB’s) beyond the recommended doses or combining two RAS inhibitors. In high-risk patients though, this more intensive RAS inhibition should be undertaken with great precaution, as tissue perfusion may be highly renin-dependent and serious adverse side effects could take place. This issue is yet to be settled as patients with significant proteinuria can be benefitted by intensive RAS inhibition. The purpose of this article is to review the evidences accrued on the use of intensive or dual blocking of RAS. We analyze potential purposes and hazards in the light of actual population data as published in recent trials.